TAS 303

Drug Profile

TAS 303

Alternative Names: TAS-303

Latest Information Update: 02 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Urologics
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stress incontinence

Most Recent Events

  • 01 Oct 2016 Phase-II clinical trials in Stress incontinence in Japan (PO) (NCT02906683)
  • 14 Sep 2016 Taiho Pharmaceutical plans an exploratory phase IIa trial for Stress incontinence in Japan (PO) (NCT02906683)
  • 01 Mar 2016 Taiho Pharmaceutical completes a phase I trial in Stress incontinence in Japan (NCT02562807)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top